Anavex Life Sciences Corp. is a Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States.
Anavex Life Sciences Corp. (AVXL) had a good day on the market for Thursday December 17 as shares jumped 10.17% to close at $6.39. About 1.88 million shares traded hands on 8,795 trades for the day, compared with an average daily volume of n/a shares out of a total float of 60.19 million. After opening the trading day at $5.77, shares of Anavex Life Sciences Corp. stayed within a range of $6.50 to $5.73.
With today’s gains, Anavex Life Sciences Corp. now has a market cap of $384.62 million. Shares of Anavex Life Sciences Corp. have been trading within a range of $7.70 and $2.21 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company operating in the United States. It is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous systems (CNS) diseases, pain and several types of cancer. The lead compound of the company is ANAVEX 2-73 which is developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. The research and development pipeline of the company includes one clinical drug candidate and several compounds in various stages of the pre-clinical study.
Anavex Life Sciences Corp. is based out of New York, NY and has some 16 employees. Its CEO is Christopher U. Missling.